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Serum cholesterol: A Superior Prognostic Marker of Sepsis Mortality in
the ICU Compared to Procalcitonin or C-reactive Protein
Abstract
Background:
Sepsis is the fourth most common admitting diagnosis to the ICU and the second leading cause of death.
Despite aggressive management, sepsis continues to have a high mortality rate as high as 48.8% and costs an
estimated $366 million annually. The need for an early prognostic marker to identify those at highest risk for
mortality in order to optimize therapeutics is critical. Procalcitonin (PCT) and C-reactive protein (CRP) are
the current standard markers in the ICU setting; however, each test carries significant limitations. Cholesterol
may be a useful prognostic marker of sepsis given that lipid metabolism is significantly altered by systemic
inflammation. These changes have been noted to occur within hours of an inflammatory state and are
negatively correlated to clinical outcome. Few studies have evaluated the efficacy of serum cholesterol
compared to PCT and CRP to identify those at high risk for mortality in the ICU. Can total cholesterol be a
superior prognostic marker of mortality in patients admitted to the ICU for sepsis compared to the current
gold standard of PCT or CRP?
Methods:
An exhaustive search was conducted using MEDLINE-Ovid, Web of Science, and CINAHL using the
following keywords: cholesterol, procalcitonin or C-reactive protein, and sepsis. Relevant articles were
assessed for quality using the Grading of Recommendations, Assessment, Development and Evaluation
(GRADE). A search on the National Institute of Health (NIH) clinical trials inquiry site indicates that there
are no current trials in any phase evaluating serum cholesterol as a prognostic marker in ICU septic patients.
Results:
Two studies met eligibility criteria and were included in this systematic review. A prospective observational
trial with 106 participants demonstrated a statistically significant superiority of total cholesterol as a
prognostic marker for septic ICU patients with infection only compared to PCT and CRP. A second
prospective observational trial with 96 participants demonstrated no superior benefit of total cholesterol
levels when compared to CRP but total cholesterol had statistically significant utility in predicting mortality
separately.
Conclusion:
Total cholesterol may be a useful and superior prognostic marker of mortality for patients admitted to the ICU
with sepsis secondary to infection compared to its CRP and PCT counterparts. Serum cholesterol could
provide ICU clinicians a more sensitive screening tool for identifying those patients at highest risk for
morbidity and mortality irrespective of other underlying comorbidities, whereas CRP may be more useful for
monitoring response to therapy. Cholesterol pathophysiology may also yield insight on experimental therapy
including the use of statin medications in septic patients in the ICU.
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Abstract   
 
Background:  
Sepsis is the fourth most common admitting diagnosis to the ICU and the second leading cause 
of death. Despite aggressive management, sepsis continues to have a high mortality rate as high 
as 48.8% and costs an estimated $366 million annually. The need for an early prognostic marker 
to identify those at highest risk for mortality in order to optimize therapeutics is critical. 
Procalcitonin (PCT) and C-reactive protein (CRP) are the current standard markers in the ICU 
setting; however, each test carries significant limitations. Cholesterol may be a useful prognostic 
marker of sepsis given that lipid metabolism is significantly altered by systemic inflammation. 
These changes have been noted to occur within hours of an inflammatory state and are 
negatively correlated to clinical outcome. Few studies have evaluated the efficacy of serum 
cholesterol compared to PCT and CRP to identify those at high risk for mortality in the ICU. Can 
total cholesterol be a superior prognostic marker of mortality in patients admitted to the ICU for 
sepsis compared to the current gold standard of PCT or CRP? 
 
Methods:   
An exhaustive search was conducted using MEDLINE-Ovid, Web of Science, and CINAHL 
using the following keywords: cholesterol, procalcitonin or C-reactive protein, and sepsis. 
Relevant articles were assessed for quality using the Grading of Recommendations, Assessment, 
Development and Evaluation (GRADE). A search on the National Institute of Health (NIH) 
clinical trials inquiry site indicates that there are no current trials in any phase evaluating serum 
cholesterol as a prognostic marker in ICU septic patients.  
 
Results:   
Two studies met eligibility criteria and were included in this systematic review. A prospective 
observational trial with 106 participants demonstrated a statistically significant superiority of 
total cholesterol as a prognostic marker for septic ICU patients with infection only compared to 
PCT and CRP. A second prospective observational trial with 96 participants demonstrated no 
superior benefit of total cholesterol levels when compared to CRP but total cholesterol had 
statistically significant utility in predicting mortality separately.  
 
Conclusion:   
Total cholesterol may be a useful and superior prognostic marker of mortality for patients 
admitted to the ICU with sepsis secondary to infection compared to its CRP and PCT 
counterparts. Serum cholesterol could provide ICU clinicians a more sensitive screening tool for 
identifying those patients at highest risk for morbidity and mortality irrespective of other 
underlying comorbidities, whereas CRP may be more useful for monitoring response to therapy. 
Cholesterol pathophysiology may also yield insight on experimental therapy including the use of 
statin medications in septic patients in the ICU.  
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Serum cholesterol: A Superior Prognostic Marker of 
Sepsis Mortality in the ICU Compared to Procalcitonin or 
C-reactive Protein 
 
BACKGROUND 
It is estimated that 5 million patients are admitted to the ICU in the United States 
annually.1 Sepsis, defined by the ACCP/SCCM Consensus Conference as the systemic 
inflammatory response to infection2 (Table I), is the fourth most common admitting diagnosis to 
the ICU and is the second leading cause of mortality in the ICU after multiorgan failure.1 Despite 
advances in aggressive management, a diagnosis of sepsis continues to have a high mortality 
rate, which increases with sepsis severity from 20.8% in patients with sepsis and as high as 
48.8% in patients with septic shock.3 Sepsis also carries a high incidence of hospital 
readmissions and consequently represents a significant portion of the healthcare budget. In a 
recent study4 evaluating 43 452 severe sepsis survivors by Goodwin et al, 26% of those patients 
were readmitted within 30 days of their discharge and 48% of survivors by 180 days, with 
associated costs estimated at $366 million and $1.1 billion, respectively. Up to 10% of the sepsis 
survivors were deceased within 180 days of discharge,4 suggesting that sepsis is associated with 
long-term morbidity and mortality.  
Currently there are few reliable therapeutic strategies for the management of sepsis 
including empiric antibiotic therapy, aggressive volume repletion, and tight insulin control. 
Given that the reversibility of severe sepsis is poor, the need for an early prognostic marker to 
identify those at highest risk for mortality in order to optimize therapeutic options is critical in 
order to reduce the ICU mortality secondary to sepsis.5 Procalcitonin (PCT), a prohormone of the 
hormone calcitonin, which is produced in the setting of microbial infection inflammatory 
mediators, and C-reactive protein (CRP), a calcium dependent ligand-binding protein 
synthesized in the liver in response to the cytokine cascade, both known acute phase proteins and 
early inflammatory markers, are the current gold standard in early diagnosis and prognosis of 
patients with sepsis in the ICU setting; however, both present with limitations in their use.6 CRP 
is a nonspecific prognostic marker that is elevated in other infectious or inflammatory disorders, 
including obesity, diabetes mellitus, systemic lupus, chronic fatigue, depression, cigarette 
smoking. Moreover, CRP may also be falsely elevated in patients on steroids.6 Evidence has 
demonstrated that PCT to be a useful tool in deciphering infectious vs noninfectious etiologies of 
inflammation5 but PCT has also had significant limitations in its utility for sepsis prognosis 
including a variable cutoff range that is dependent on the clinical setting and comorbidities such 
COPD and immunosuppression. PCT also has a high rate of false-positive and false-negative 
results (Table II).6 
Recent evidence7 suggests that serum cholesterol may be a useful prognostic marker of 
sepsis given that cholesterol metabolism has been shown to be markedly influenced by a state of 
widespread inflammation secondary to bacteremia. Additional studies5 have demonstrated that 
patients diagnosed with severe sepsis in the ICU have a measured decrease in circulating levels 
of lipoproteins and an increase in triglycerides independent of comorbidities. These changes 
have been noted to occur early (within hours) in the inflammatory cascade associated with 
sepsis. A reduction in serum cholesterol was also negatively correlated to clinical outcome and 
length of stay, which carries additional mortality risk.8  
Few studies, however, have evaluated the efficacy of serum cholesterol compared to the 
current gold standards, which have significant limitations in diagnosing sepsis early and 
accurately identify those at high risk for mortality in the ICU setting. Can total cholesterol be a 
superior prognostic marker of mortality in patients admitted to the ICU for sepsis compared to 
the current gold standard of procalcitonin or C-reactive protein? 
 
METHODS 
An exhaustive search of available medical literature was conducted using MEDLINE-
Ovid, Web of Science, and CINAHL using the following keywords: cholesterol, procalcitonin or 
C-reactive protein, and sepsis. Studies were included if the primary data evaluated the prognosis 
of adult patients admitted to the ICU for sepsis using cholesterol levels compared to one or both 
PCT or CRP. All studies evaluated must have been published in English and data collected using 
human trials only. Articles were excluded if trials were conducted on surgical ICU patients or if 
the primary data collected was on statin efficacy. Relevant articles were assessed for quality 
using the Grading of Recommendations, Assessment, Development and Evaluation (GRADE).19 
A search on the National Institute of Health (NIH) clinical trials inquiry site indicates that there 
are no current trials in any phase evaluating serum cholesterol as a prognostic marker in ICU 
septic patients.  
 
RESULTS 
The initial result of the search yielded 36 potential articles. A total of 2 articles9,10 met 
eligibility criteria after screening relevant articles for primary data and human studies published 
in English. Both relevant articles were prospective observational studies published after 2007 
(Table III and IV).  
 
Cholesterol rather than procalcitonin or C-reactive protein predicts mortality in patients 
with infection (Biller et al) 
 
In this prospective observational study,9 the authors compared the prognostic effect of 
serum total cholesterol levels to PCT and CRP in predicting mortality in adult patients admitted 
to the ICU with severe sepsis secondary to infectious etiologies only. The study included patients 
admitted to the ICU at the University Hospital Grohadern in Munich, Germany. Seventy-six 
patients admitted consecutively to the ICU for sepsis secondary to infection between 2007 and 
2011 fulfilling sepsis criteria of the ACCP/SCCM Consensus Conference2 were included in the 
study. Infection was defined according to the Center for Disease Control criteria with bacterial 
proof and either an elevated CRP upon admission, signs of infection, including fever, shaking 
chills, and local signs, or radiological evidence. A control group of 40 patients admitted to the 
ICU with systemic inflammatory response syndrome (SIRS), a systemic inflammatory condition 
without evidence of infection, were also included in the study as controls. A one time blood draw 
was done immediately upon admission to the ICU to measure total cholesterol, PCT, and CRP.9  
The primary outcome was mortality, which was investigated for the entire length of stay 
in the ICU per patient. Additional data collected upon hospital admission included the etiologies 
of infection and sepsis severity using the ACCP/SCCM criteria.2 In-house mortality and 
underlying comorbid disorders were also considered during data analysis. Infectious etiologies of 
sepsis included pneumonia (most common), peritonitis, wound infection, bacteremia, urinary 
tract infection, and pancreatitis. Gram-negative infections predominated and aerobic infections 
were more common than anaerobic bacterial infections.9 
Data analysis demonstrated that total cholesterol levels were significantly lower in 
nonsurviving patients in comparison with surviving patients (P = 0.006, 69mg/dL [range 37-
88mg/dL] vs 96mg/dL [range 71-132mg/dL) whereas PCT and CRP levels demonstrated no 
significant difference between the two groups. ROC analysis showed an AUC of 0.715 for total 
cholesterol levels and survival, with AUCs of 0.407 and 0.474 for PCT and CRP, respectively. 
Of the patients with sepsis and a total cholesterol level of 50mg/dL or less, 82% of the patients 
did not survive whereas patients with a cholesterol level of 100mg/dL or greater had a mortality 
rate of only 21%. A total cholesterol level of 80mg/dL was associated with a sensitivity of 72% 
and a specificity of 66%. There was no significant difference between survivors and 
nonsurvivors in the control group for all prognostic markers,9 suggesting that cholesterol may be 
most valuable in patients with sepsis secondary to infection rather than noninfectious etiologies 
of SIRS.  
The authors suggest that a decrease in total cholesterol (hypocholesterolemia), which is 
consistent with previous research, has prognostic significance in patients with sepsis whereas 
PCT and CRP failed to demonstrate superior predictive value of mortality in this patient 
population. It is recommended that on admission total cholesterol levels may identify patients at 
high risk for mortality with sepsis, enabling more optimal clinical management of these patients 
to prevent death.9 
 
High C-reactive protein and low cholesterol levels are prognostic markers of survival in 
severe sepsis (Memis et al) 
 
This prospective observational study10 evaluated the predictive potential of total 
cholesterol in patients admitted to the Trakya University Hospital ICU in Turkey with sepsis in 
comparison with CRP only. Included were 96 patients admitted to the ICU for bacteriologically 
documented infections and at least two of the severe sepsis parameters defined by the 
ACCP/SCCM Consensus Conference.2 Patients were excluded if they were admitted for 
infections secondary to burns, admitted for trauma, receiving coronary management, 
immunosuppressed patients, or diagnosed with a lethal condition that would result in death 
within 24 hours of admission. All patients were noted to receive standard of care resuscitation 
management and broad-spectrum antibiotic therapy, which included an aminoglycoside and a 
fourth generation cephalosporin or ciprofloxacin. Antibiotic management was altered in response 
to culture sensitivities accordingly. Total cholesterol and CRP levels were drawn within the first 
24 hours of admission, day 2, and on the day of discharge from the ICU or upon death. The 
primary outcome was mortality, which was observed for 27 months following admission to the 
ICU. Clinical status and sepsis severity were monitored with the APACHE II score daily.10   
Early data analysis indicated that nonsurvivors tended to be older in age and had higher 
CRP and APACHE II scores on admission compared to their survivor counterparts. In order to 
account for confounding factors of age on cholesterol levels, a covariance test was used to 
remove the confounding effect. It was then demonstrated that nonsurvivors did have significantly 
lower cholesterol levels compared to survivors on Day 1, 2, and the last day (P <0.001, P < 
0.001, P = 0.001, respectively). ROC analysis for Day 1 indicated that total cholesterol and 
survival had an AUC of 0.987 on admission with a sensitivity and specificity of 97.6% and 
100%, respectively, whereas CRP with survival had an AUC of 0.947 with a sensitivity and 
specificity of 97.6% and 80%, respectively. There was no statistically significant difference 
between CRP and total cholesterol levels.10 
The authors conclude that monitoring for hypocholesterolemia may be an equally 
effective prognostic marker of mortality risk as compared to CRP but may be superior if in 
addition to scoring systems that take into consideration severity of illness and age such as the 
APACHE II assessment. This combination of resources would then allow clinicians in the ICU 
setting to earlier identify those patients that require careful monitoring and more aggressive 
therapies for sepsis and sepsis complications.10  
 
DISCUSSION 
Sepsis and septic shock have long remained one of the most common yet most 
challenging admission diagnoses in the ICU, with significant risk for morbidity and mortality 
despite current aggressive management and high healthcare costs.3 Recent focus has been 
directed at identifying a prognostic marker to identify those patients that are at highest risk of 
mortality in the ICU secondary to sepsis. PCT and CRP, the most avidly studied prognostic 
markers, have demonstrated promise; however, significant limitations have been identified 
including lack of sensitivity and specificity as well as risk of false results with other 
comorbidities.7 Although recognized for its diagnostic utility, CRP may be best utilized as a 
measure of response to therapy and the severity of inflammation rather than a prognostic marker 
given its relatively short half-life (approximately 19 hours).10 Prognostic potential of PCT is 
unlikely during the early phase of systemic inflammation; however, without larger studies, the 
true effect compared to total cholesterol is unknown.9  
Hudgins et al,11 in a study evaluating the systemic inflammatory response in both septic 
patients and healthy volunteers injected with a low dose of endotoxin, found that there is a major 
disruption in the normal metabolism of lipids, including lower levels of circulating HDL-C and 
the loss of one of the most abundant HDL apolipoproteins, Apo-A1. Low levels of Apo-A1 have 
been demonstrated throughout the literature to be significantly lower in nonsurviving septic 
patients compared to survivors.12 Changes in plasma lipids have been demonstrated to occur very 
early in systemic inflammation, with evidence that HDL-C decreases within hours of systemic 
cytokine stimulation,8 suggesting that plasma lipids, specifically HDL-C and Apo-A1 levels, 
may have significant promise as a sensitive prognostic markers of mortality in patients admitted 
to the ICU with sepsis. Although both prospective studies9,10 demonstrate high specificity, 
Windler et al13 suggest that the convenience of total cholesterol is its nonspecificity for any 
particular disease, which make low serum cholesterol a potential universal marker of mortality 
for a spectrum of diagnoses in the ICU. Unlike CRP and PCT, which can be altered with other 
underlying diseases, low cholesterol levels have been reported in a large population study as 
useful prognostic marker irrespective of comorbidities at time of admission.13 Reductions in 
cholesterol, which do occur frequently in a hospital setting, were unlikely to decrease below 
100mg/dL, whereas nonsurviving patients often had cholesterol levels as low as 40mg/dL.13 
Serum cholesterol levels below 100mg/dL, which are only found in abetalipoproteinemia 
disorders, are rare and would be unlikely to alter the significance of hypocholesteremia in severe 
disease, including sepsis.13  
Although the exact mechanism in HDL-C and Apo-A1 reduction is relatively unknown, it 
is theorized that cholesterol’s role in the innate immune system may be to blame, rendering the 
host more susceptible to subsequent injury secondary to inflammation. Several studies have 
indicated that cholesterol has protective immunomodulatory effects in the presence of gram-
negative sepsis,7 HDL-C and Apo-A1 in particular, being implicated as key players in the innate 
immune cascade in response to infection by binding and subsequently neutralizing 
lipopolysaccharide (LPS) endotoxins as well as lipoteichoic acid.14 These formed complexes 
result in consumption of HDL-C with high production of endotoxin, as seen in sepsis, resulting 
in a decline in circulating HDL-C and subsequently the immunomodulating effect that HDL-C 
has in response to infection.12 This is consistent with Biller et al,9 which demonstrated that a 
reduction in cholesterol has value as a prognostic marker in patients with infection but not in 
patients with systemic inflammation without infection. This supports the hypothesis that HDL 
lipoproteins, comprising more than 90% of circulating cholesterol, have a prognostic role in 
infection.9 It is also theorized that a subsequent massive production in proinflammatory 
cytokines secondary to infection may suppress the production of necessary apolipoproteins by 
the liver, which leaves tissue more vulnerable to endotoxin-mediated harm.12 It is also possible 
that the reduction in HDL-C and Apo-A1 may be independent of the innate immune system role 
of cholesterol and rather a result of altered secondary to endogenous tissue lipid metabolism 
inhibition or increased hepatic triglyceride production (“lipemia of sepsis”).15 Low levels of 
HDL-C have also been associated with low levels of stress-induced glucocorticoid production, 
which is a key innate response in combating the clinical manifestations of systemic inflammation 
as well as altered leukocyte recruitment.16  
While the studies9,10 demonstrated that total cholesterol may have significant utility as a 
superior prognostic marker of mortality in ICU septic patients, they both are limited in regards to 
evidence quality being observational studies and small sample sizes with inadequate control 
groups. Although the data in the Biller et al9 study demonstrated convincing evidence that total 
cholesterol is a superior prognostic marker compared to the current gold standards, the lack of 
precision in comparing 37 nonsurvivors to 29 surviving patients demotes the quality of the 
evidence significantly on the basis of sample size. Their evaluation of hypocholesteremia 
severity with mortality rate is promising, however, and is consistent with previous studies that 
suggest a correlation to the severity of hypocholesterolemia and mortality (Figure I). In their 
study, 82% of patients with a serum total cholesterol level less than 50mg/dl during their ICU 
stay did not survive in comparison to their counterparts with cholesterol levels greater than 
100mg/dL, who had a mortality rate of 21%. Windler et al13 indicated in a study comprising of 
61 463 hospitalized septic participants that patients with serum cholesterol levels of 100mg/dL or 
less had an increased mortality rate of 29.7% from 3.6% in patients with normal cholesterol 
levels. Every patient with a serum cholesterol level less than 40mg/dL during their hospital stay 
did not survive.13  
Likewise, Memis et al10 failed to provide precision given that their study was limited to 
96 patients admitted to the ICU with documented infection and sepsis without a control group for 
comparison. However, of significance in this study, serum cholesterol levels and CRP were 
monitored over time (within 24 hours of admission, day 2, and day of discharge or death) with 
evidence that total cholesterol levels and CRP had significant prognostic ability throughout a 
patient’s hospital stay (P < 0.001),10 suggesting that total cholesterol levels may have utility 
beyond that of admission. 
In addition, neither Biller et al9 or Memis et al10 considered additional significant 
prognostic endpoints, including hospital length of stay (LOS) and the number of ventilator days. 
In a study evaluating inflammatory markers in their prognostic utility for adverse outcomes in 
blunt trauma and sepsis, it was found that total cholesterol within the first week of admission are 
inversely related to the number of days on a ventilator and the hospital LOS,17 suggesting that 
serum cholesterol has additional significant prognosis utility beyond mortality. Although 
previous studies18 have demonstrated that pre-existing dyslipidemia disorders, including those 
requiring lipid-lowering therapy, do not confound serum cholesterol results in septic patients in 
the ICU, it is a serious variable to consider in evaluating the serum lipid response during 
systemic inflammation.  
 
CONCLUSION 
Emerging evidence suggests that serum total cholesterol may be a useful and superior 
prognostic marker of mortality for patients admitted to the ICU with sepsis secondary to 
infection compared to its CRP and PCT counterparts. With larger, more comprehensive studies, 
it is likely that evidence will indicate that serum cholesterol levels will provide ICU clinicians a 
more sensitive screening tool for identifying those patients at highest risk for morbidity and 
mortality irrespective to other underlying comorbidities, whereas CRP may be more useful for 
monitoring response to therapy. Monitoring serum cholesterol levels on hospital admission could 
provide a very novel, inexpensive tool that has the potential to start early and aggressive therapy 
in patients most at risk for death, thus decreasing the mortality rate secondary to sepsis. 
Understanding the pathophysiology of lipid metabolism in the event of systemic inflammation 
also opens the door to additional experimental therapy including the use of statin medications in 
septic patients.  
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Table I.  ACCP/SCCM Definition of Sepsis 
 
 
 
Table II.  False-positive and false-negative results of PCT assay 
 
 
 
 
Table III.  Characteristics of Reviewed Studies (GRADE) 
 
Quality Assessment 
 Downgrade Criteria  
Studies Design Limitations Indirectness Imprecision Inconsistency Publication bias Quality 
Mortality (All-Cause) 
Biller et al9 Prospective Observational 
No serious 
limitations 
No serious 
indirectness 
Limited sample 
size 
No serious 
inconsistencies No bias likely Very low 
Memis et al10 Prospective Observational 
No serious 
limitations 
No serious 
indirectness 
Limited sample 
size without control 
group 
No serious 
inconsistencies No bias likely Very low 
 
 
 
 
 
 
 
 
 
 
 
 
Table IV.  Summary of Findings 
 Number of Patients Effect 
Study Isolated infection Control Time Marker Sens % Spec % AUC 
Mortality (All-cause) 
Biller et al9 76/106 40/106 Day 1 
TCH 72% 66% 0.715 
CRP NA NA 0.407 
PCT NA NA 0.474 
Memis et al10 96/96 NA 
Day 1 
TCH 97.6% 100% 0.987 
CRP 97.6% 80% 0.947 
Day 2 
TCH 97.6% 92.7% 0.985 
CRP 90.2% 96.4% 0.975 
Last Day* 
TCH 92.7% 96.4% 0.973 
CRP 100% 96.4% 0.997 
Abbreviations: 
TCH: Total cholesterol 
CRP: C-reactive protein 
PCT: Procalcitonin 
AUC: Area under the curve 
*Last day was measured as either day of discharge or day of death 
 
 
 
 
 Figure 1A. Cholesterol serum levels of survivors and nonsurvivors in patients with 
infection; 1B. Mortality in relation to quartiles of cholesterol levels. 
 
 
 
